Impact Partnership Wealth LLC Has $1.37 Million Stock Holdings in Illumina, Inc. $ILMN

Impact Partnership Wealth LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 235.8% in the first quarter, HoldingsChannel.com reports. The fund owned 11,080 shares of the life sciences company’s stock after acquiring an additional 7,780 shares during the quarter. Impact Partnership Wealth LLC’s holdings in Illumina were worth $1,366,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Capital World Investors raised its stake in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Invesco Ltd. lifted its position in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares during the period. AQR Capital Management LLC grew its stake in Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after buying an additional 1,028,099 shares in the last quarter. Morgan Stanley grew its stake in Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after buying an additional 1,005,474 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after buying an additional 911,843 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ILMN shares. Barclays boosted their target price on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Thursday, May 14th. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $147.18.

Illumina Stock Down 2.9%

ILMN stock opened at $175.83 on Wednesday. The stock has a market capitalization of $26.60 billion, a P/E ratio of 31.97, a price-to-earnings-growth ratio of 3.39 and a beta of 1.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $182.84. The firm has a 50-day moving average price of $151.42 and a 200-day moving average price of $138.36.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the sale, the insider owned 20,953 shares of the company’s stock, valued at approximately $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,003,769 shares of company stock worth $155,710,908. Corporate insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.